The DUS3L Knockout SK-HEP-1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line. This heterogeneous pool of cells carries targeted disruption of the DUS3L gene, providing a loss-of-function model without single-cell clonal isolation. The polyclonal format mitigates clonal artifacts and retains genomic diversity, enabling population-level analyses of DUS3L function in liver cancer signaling.
SK-HEP-1 is a cell line originally established from the ascitic fluid of a patient with liver adenocarcinoma. Although its lineage has been debated, it is widely employed in hepatocellular carcinoma research due to its robust growth and well-characterized signaling networks. The cells exhibit adherent, epithelial-like morphology and serve as a relevant host for dissecting MAPK-driven oncogenic processes. Their responsiveness to growth factors and stressors makes them an ideal background for studying phosphatase-mediated regulation of the MAPK cascades.
DUS3L encodes a putative dual-specificity phosphatase that negatively regulates MAPK signaling by dephosphorylating key kinases. It directly interacts with and dephosphorylates MAPK1 (ERK2), MAPK8 (JNK1), and MAPK14 (p38??), thereby attenuating signal transduction. Upstream regulators include cellular stress, TNF-??, and EGF, which modulate DUS3L activity. Within the cascade, DUS3L acts downstream of RAS, RAF1, and MAP2K1 (MEK1) to counterbalance phosphorylation, and functions alongside other phosphatases such as DUSP6 to fine-tune pathway output. Disruption of DUS3L is anticipated to lead to sustained activation of ERK, JNK, and p38 pathways.
In the SK-HEP-1 context, DUS3L knockout likely amplifies pro-tumorigenic MAPK signaling, enhancing proliferation, migration, and invasion while suppressing apoptosis. These phenotypic changes mirror key aspects of hepatocellular carcinoma progression, where MAPK pathways are frequently hyperactivated. The model thus permits exploration of DUS3L as a potential tumor suppressor and a node of therapeutic intervention. By comparing wild-type and knockout populations, researchers can dissect the contribution of DUS3L to stress responses and drug sensitivity in liver cancer.
The DUS3L Knockout SK-HEP-1 Polyclonal Cells support a broad range of functional assays. Western blotting with phospho-specific antibodies detects hyperphosphorylation of MAPK1, MAPK8, and MAPK14 upon DUS3L loss. RT-qPCR quantifies downstream transcriptional changes, while proliferation (MTT, BrdU) and migration/invasion assays assess tumorigenic behavior. Flow cytometry enables apoptosis and cell cycle profiling, and RNA-seq facilitates global transcriptomic analysis. These cells are invaluable for studying MAPK regulation, validating drug targets, and screening kinase inhibitors in liver cancer. For further assistance, please contact Ascent Research.
